OncoMatch/Clinical Trials/NCT06005870
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Is NCT06005870 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Zanubrutinib plus RCHOP for diffuse large b cell lymphoma.
Treatment: Zanubrutinib plus RCHOP — This study aim to evaluate the efficacy and safety of zanubrutinib combined with R-CHOP in the treatment of DLBCL patients with p53 protein expression.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: TP53 overexpression (≥50% by immunohistochemistry)
Patients with positive p53 expression detected by immunohistochemistry (≥50%)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
neutrophil count (NEUT) ≥1.5×10^9/L, platelet count (PLT) ≥75×10^9/L, hemoglobin (HGB) ≥80 g/L; G-CSF not used in past 7 days (lymphoma-induced cytopenia could be included)
Kidney function
serum creatinine (Cr) ≤2.0×ULN or creatinine clearance (CCr) ≥60ml/min
Liver function
Total bilirubin (TBIL) ≤1.5× ULN; ALT and AST ≤2.5×ULN; If liver metastases present, TBIL≤3×ULN, ALT and AST≤5×ULN
Cardiac function
LVEF≥50%, ECG did not indicate any acute myocardial infarction, arrhythmia, or atrioventricular conduction block above grade I
The patients had certain conditions of organ function reserve, and the laboratory tests within 1 week before enrollment met the following conditions: ... (see above for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify